Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Runners-up this week include litigators at Paul Hastings, Williams & Connolly, King & Spalding, McFarland Litigation Partners ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" data-type="post" data-object_id="321117" class="cbxwpbkmarktrig ...

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...

Novartis said that the latest round of job losses is a result of a change in focus for its cardiovascular teams as they lower the emphasis on Entresto and devote more resources to its twice-yearly ...

Global drugmaker Novartis will lay off 427 employees in East Hanover this spring and summer, after it let go of 235 at the ...

The notice comes three months after the pharmaceutical giant said it would eliminate 139 jobs at the location between February and August.